




# GLY-CoP

Perioperative **G**lycaemic **C**ontrol in **P**ancreas  
Transplant Recipients: A Feasibility Study


**Mr Rory Brown**

ST7 (OOPR) | Clinical Research Fellow  
Manchester Centre for Transplantation

# The problem



# What we have shown




# What we don't know

hyperglycaemia → early graft failure?

# The Solution

Tight glycaemic control  
( $<7\text{mmol/L}$ )

Standard care



Graft survival

## The Trial

**Feasibility trial:** Single arm study of the intervention arm

**Full trial:** Randomised controlled trial of the intervention versus standard care

### Inclusion:

- Type-1 diabetics listed for solid-organ pancreas transplantation

### Exclusion:

- Previous pancreas transplant, age <18, inability to provide informed consent

**Feasibility trial sample size:** 20 participants

- Enables us to detect 87% recruitment with a 95% binomial CI of 66.4-97.2%.

## The Intervention

### Variable rate insulin infusion:

- Study specific protocol adapted from Portland
- 4.0 – 6.9mmol/L
- 5 days postoperatively


### Safety Features:

- Dexcom 7 CGM
- Discontinued on step down to ward
- Central blood samples
- Escalation of increasing insulin requirement


# Primary Outcomes

	Recruitment	Completeness	Safety	Adherence
Measure	Percentage of eligible patients who enrol in the study	Percentage of participants with completed 90-day HbA1c	Percentage of participants experiencing $\geq 1$ severe hypoglycaemic events ( $\leq 2.2\text{mmol/l}$ ) during the intervention	Mean percentage time spent in target glycaemic range (4.0-6.9mmol/L) during the intervention period
<b>Red</b>	<66%	<80%	>20%	<60%
<b>Amber</b>	66 - 87%	80 - 100%	11 - 20%	60 - 70%
<b>Green</b>	>87%	100%	<11%	>70%


Feasibility Trial



HbA1c at 1 year



Full Trial



### **The team:**

Mr D. van Dellen (Consultant Transplant Surgeon)

Mr R. Brown (SpR - Transplant Surgery)

Dr H. Thabit (Consultant Endocrinologist)

Dr J. Bannard-Smith (Consultant Intensivist)

Mr I. Shapey (Consultant Pancreatic Surgeon)

Dr Catherine Fullwood (Senior Statistician)

Mr Andrew Freeman (Patient Partner)

Mrs Tauseefha Bint-Taufiq (Patient Partner)

### **Sponsor:**

Manchester University NHS Foundation Trust

Sponsored as non-CTIMP study

## **What's Next?**

Funding



Ethical approval



## References

- Fridell JA, Niederhaus S, Curry M, Urban R, Fox A, Odorico J. The survival advantage of pancreas after kidney transplant. *Am J Transplant*. 2019;19(3):823–30.
- NHSBT. Organ and Tissue Donation and Transplantation Activity Report 2023/2024 [Internet]. [cited 2025 Feb 27] p. 52. Available from: <https://nhsbt.dbe.blob.core.windows.net/umbraco-assets-corp/33779/activity-report-2023-2024.pdf>
- Shapey IM, Tan ZL, Gioco R, Khambalia H, Fullwood C, Yiannoullou P, et al. Peri-transplant glycaemic control as a predictor of pancreas transplant survival. *Diabetes Obes Metab*. 2021;23(1):49–57.
- Van den Berghe G, Wilmer A, Milants I, Wouters PJ, Bouckaert B, Bruyninckx F, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. *Diabetes*. 2006 Nov;55(11):3151–9.
- Finfer et al. Intensive versus Conventional Glucose Control in Critically Ill Patients. *N Engl J Med*. 2009 Mar 26;360(13):1283–9
- Gunst J, Debaveye Y, Güiza F, Dubois J, Bruyn AD, Dauwe D, et al. Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU. *N Engl J Med*. 2023 Sep 27;389(13):1180–90
- Finfer S, Wernerman J, Preiser JC, Cass T, Desai T, Hovorka R, et al. Clinical review: Consensus recommendations on measurement of blood glucose and reporting glycaemic control in critically ill adults. *Crit Care*. 2013 Jun 14;17(3):229.
- Rickels MR, Stock PG, de Koning EJP, Piemonti L, Pratschke J, Alejandro R, et al. Defining Outcomes for  $\beta$ -cell Replacement Therapy in the Treatment of Diabetes: A Consensus Report on the Iglc Criteria From the IPITA/EPITA Opinion Leaders Workshop. *Transplantation*. 2018 Sep;102(9):1479–86.
- Kourounis G, Tingle SJ, Maillo-Nieto A, Wroe C, Thompson ER, Owen R, et al. One-Year HbA1c Predicts Long-Term Pancreas Graft Survival Following SPK Transplantation: A US Population Cohort Study. *Transpl Int*. 2025 Aug 6;38:14940.

Please help by informing us what is your perioperative practice in following pancreas transplantation with this short survey:

